Cabozantinib for soft tissue sarcoma – pro
Some studies support cabozantinib’s effect on targets in vitro and one for efficacy that did not show efficacy for soft tissue sarcoma bin general, but O’Sullivan Coyne et al found that Cabozantinib single-agent antitumor activity was observed in patients with selected STS histologic subtypes (alveolar soft-part sarcoma, undifferentiated pleomorphic sarcoma, extraskeletal myxoid chondrosarcoma, and leiomyosarcoma. Shoffsski et al in a review concluded that cabozantinib has shown promising activity for the treatment of various sarcomas, supporting further evaluation in this setting.A randomized phase II trial in soft tissue sarcoma is ongoing, as reported by Eulo et al, but the specific subtype of alveolar soft tissue sarcoma is too rare to be studied by itself
Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. Curr Opin Oncol. 2020 Jul;32(4):321-331.
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.Clinical O’Sullivan COynet et an l, Cancer Research: an Official Journal of the American Association for Cancer Research, 29 Oct 2021, 28(2):279-288
V.A. Eulo et al, A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.Journal of Clinical Oncology 39, no. 15_suppl. Published online May 28, 2021.